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Abstract
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Insulin from the β-cells of the pancreatic islets of Langerhans controls energy homeostasis in
vertebrates, and its deficiency causes diabetes mellitus. During embryonic development, the
transcription factor Neurogenin3 initiates the differentiation of the β-cells and other islet cell types
from pancreatic endoderm, but the genetic program that subsequently completes this
differentiation remains incompletely understood. Here we show that the transcription factor Rfx6
directs islet cell differentiation downstream of Neurogenin3. Mice lacking Rfx6 failed to generate
any of the normal islet cell types except for pancreatic-polypeptide-producing cells. In human
infants with a similar autosomal recessive syndrome of neonatal diabetes, genetic mapping and
subsequent sequencing identified mutations in the human RFX6 gene. These studies demonstrate a
unique position for Rfx6 in the hierarchy of factors that coordinate pancreatic islet development in
both mice and humans. Rfx6 could prove useful in efforts to generate β-cells for patients with
diabetes.

Author Manuscript

During embryonic development, the pancreas first appears as clusters of cells on the dorsal
and ventral aspects of the gut endoderm. The exocrine and endocrine cells that form the
adult pancreas differentiate from this pool of pancreatic progenitors 1. A single transcription
factor, the pro-endocrine bHLH factor Neurogenin3, is both necessary and sufficient to drive
these progenitor cells to differentiate into the endocrine cells that form the islets of
Langerhans 2,3,4. Transient activation of Neurogenin3 expression in scattered progenitor
cells initiates expression of additional transcription factors, including NeuroD1, Pax4,
Nkx2.2, Nkx6.1, Arx, and others, which then direct the differentiation of those cells into the
distinct islet cell subtypes and the activation of the mature islet transcription factors such as
MafA, Pax6 and Isl1 1. Mutations in many of these genes can cause diabetes, highlighting
the pathway’s importance in human beta-cell formation and insulin production5.
Understanding and controlling this process of differentiation may ultimately provide us with
the cells needed to treat diabetes mellitus.

Expression of Rfx6

Author Manuscript

In independent screens for genes co-expressed with Neurogenin3 in islet progenitor cells 6,
activated by Neurogenin3 7, and uniquely expressed in islets (M.E.W. and J.D.J.,
unpublished data), we identified Rfx6, a member of the RFX (Regulatory Factor X-box
binding) family of winged-helix transcription factors 8,9. Rfx6 transcripts could be detected
in mouse and human embryonic pancreas by RT-PCR (Fig. 1a,b), but, unlike all other
known islet transcription factors, not in brain (Fig. 1a, c), and not in mouse embryonic
pancreas lacking Neurogenin3 (Fig. 1d). In contrast, mouse Rfx4, the mammalian RFX gene
with the highest homology to Rfx6, was amplified from brain and not from pancreas, and the
other RFX genes were more widely expressed (Fig.1a).
To explore the pattern of Rfx6 protein expression, we used antiserum generated against
recombinant Rfx6 protein for immunofluorescence studies. In mice, Rfx6 was detected as
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early as embryonic day 7.5 (e7.5) throughout the definitive, but not extraembryonic,
endoderm and persisted broadly in gut endoderm at e9.0, after which it becomes
progressively restricted to the pancreas and scattered cells in the gut (Fig. 2a-c,
Supplemental Fig. S1 and data not shown). At e10.0, immunofluorescence staining detected
Rfx6 in foregut/midgut epithelium and in scattered cells in the nascent pancreatic buds, as
indicated by staining for pancreatic transcription factor Pdx1 (Fig. 2d-f). Most of these
scattered Rfx6-expressing cells did not co-express Pdx1, but many co-expressed Nkx2.2 and
Neurogenin3 (Supplemental Figs. S1 and S2). By e12.5, the Rfx6-expressing cells were
generally distinct from the Pdx1-expressing progenitor cells, but most co-expressed
glucagon, demonstrating restricted expression of Rfx6 in the endocrine lineage even at this
early stage (Supplemental Fig. S3). In pancreata from Neurog3-/- embryos 10, there were no
Rfx6-expressing cells (Supplemental Fig. S4).

Author Manuscript

During the peak of endocrine cell differentiation at e15.5, Rfx6 co-localized with
Neurogenin3 in the nuclei of a subset of the endocrine progenitor cells (Fig 2g), and
overlapped with the islet transcription factors Nkx2.2, Nkx6.1, and Pdx1 (Supplemental Fig.
S5). At e18.5, Rfx6 could be found in the nuclei of cells expressing each of the major
pancreatic endocrine hormones (Fig. 2h and Supplemental Fig. S6). In the adult pancreas,
Rfx6 expression was restricted to the islets where it could be detected in all endocrine
lineages (Fig.2i and Supplemental Fig. S7).

Author Manuscript

To generate Rfx6 null mice, we used homologous recombination to replace the first five
exons of the Rfx6 gene, including the sequences encoding the DNA-binding domain, with a
cassette encoding an eGFP-cre fusion protein (Supplementary Fig. S8). By crossing mice
heterozygous for the mutant allele with mice carrying the marker gene ROSA26 loxP-stoploxP lacZ (R26R) 11, we generated Rfx6+/eGFPcre/R26R double heterozygous mice in which
Rfx6-expressing cells and their descendents are marked by the expression of β-galactosidase
and can be visualized with the X-gal substrate (Fig. 3a-d and Supplemental Fig. S9). βgalactosidase expression was detected in all embryonic tissue derived from the endoderm
germ layer, but not in other embryonic or in extraembryonic tissues, demonstrating that
Rfx6 is broadly expressed in and restricted to the definitive endoderm prior to the formation
of the endoderm-derived organs. Taken together, the immunohistochemistry data and
lineage tracing demonstrate that Rfx6 is expressed initially broadly in the definitive
endoderm after gastrulation, becomes restricted to the gut and pancreatic bud at mid
gestation, is reactivated by Neurogenin3 in islet progenitor cells and is ultimately restricted
to pancreatic islets in the mature pancreas.

Rfx6eGFPcre/eGFPcre mice
Author Manuscript

From heterozygous crosses, homozygous Rfx6eGFPcre/eGFPcre mice were born at the
expected Mendelian ratio, but failed to feed normally, exhibited gross bowel distension due
to small bowel obstruction (Fig. 3e-f) and died within 2 days post partum. Some, but not all,
of the Rfx6 null animals also had reduced pancreas size (data not shown).
To test for effects on gene expression prior to birth, we harvested RNA from e17.5
pancreata, and used low density TaqMan arrays 6 to measure the levels of a set of pancreatic
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genes (Supplemental Table S1). Rfx6 eGFPcre/GFPcre pancreata had almost no expression of
the islet hormones genes, except for pancreatic polypeptide (Ppy). Several other islet/β-cell
genes, such as the zinc transporter Slc30a8 and G-protein coupled receptor GPR40/Ffar
genes, were similarly reduced; but other β-cell genes were more modestly reduced, including
the glucose sensing genes Gck, Slc2a2, and Kcnj11. Immunofluorescence staining with the
endocrine markers Chromogranin A or Synaptophysin at e17.5 demonstrated that the
Rfx6 eGFPcre/eGFPcre pancreata still contained a large number of endocrine cells, but
confirmed that none of these cells expressed insulin, glucagon, somatostatin or ghrelin (Fig.
4). Although the number of Ppy-expressing cells was increased in the Rfx6 eGFPcre/eGFPcre
pancreata, they only accounted for a subset of the endocrine cells (Fig. 4i-l), leaving the
identity of the remaining endocrine cells unknown.

Author Manuscript

We also tested whether Rfx6 regulates other transcription factor genes (Supplemental Table
S2). The absence of Rfx6 did not affect Neurogenin3 expression, and this was confirmed at
the protein level (data not shown). In sharp contrast, expression of genes downstream of
Neurogenin3 encoding factors involved in alpha-cell development, including Irx2 and Arx,
was markedly reduced in Rfx6 eGFPcre/eGFPcre pancreata.

Author Manuscript

Interestingly, genes encoding several factors involved in insulin gene transcription (Pax6,
MafA, NeuroD1 and Pdx1) also had reduced expression, but some key genes involved in βcell specification either did not significantly change (Nkx2.2 and Nkx6.1), or increased
(Pax4). Immunofluorescence staining at e17.5 revealed that the field of Nkx6.1 expression
expanded from β-cells alone in wildtype pancreata to include all of the Chromogranin A +
endocrine cells, including the PP cells in Rfx6 eGFPcre/eGFPcre pancreata (Fig. 4i-l and
Supplementary Table S3). These studies suggest that while Rfx6 regulates the transcription
factors involved in β-cell maturation and function, it restricts the expression of the β-cell
differentiation and specification genes, and thus the β-cell fate choice.

Author Manuscript

Mice with a targeted disruption of the Rfx3 gene have an islet phenotype that is similar to,
but less extreme than, the Rfx6 eGFPcre/eGFPcre mice, with reductions in the numbers, but not
complete loss, of insulin- and glucagon-expressing cells and an increase in pancreatic
polypeptide-expressing cells 12. In a proteome-wide screen of protein-protein interactions,
Rfx6 was found to interact with Rfx2 and 3 13. Since the RFX transcription factors generally
bind to their target DNA sites (the “X box”) as dimers 14, we tested whether Rfx6 and Rfx3
form a heterodimeric DNA binding complex in an electromobility shift assay (EMSA). We
found that both full length Rfx3, and truncations that retain the DNA-binding and
dimerization domains, bound to an X box site together with Rfx6 (Fig. 5a and
Supplemenatry Fig. S10), and that the two factors cooperated in activating a promoter
containing multimers of this X box site (Fig 5b).
It has been proposed that the islet phenotype of the Rfx3-/- mice results from defects in
primary cilia formation on islet cells 12, although islets lacking any primary cilia develop
fairly normally 15,16. Unlike in the Rfx3-/- mice, we found that primary cilia formation was
unaffected in the Rfx6 eGFPcre/eGFPcre islets (Supplementary Fig. 11a-d). In addition,
expression of the cilia genes Ift88 and Dync2li1, which are reduced in the pancreas of Rfx3-/mice12, was not reduced in the pancreas of Rfx6 eGFPcre/eGFPcre mice (Supplementary Fig.
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11e). We conclude that Rfx3 and Rfx6 cooperate in regulating a set of genes involved in
islet development but not in cilia formation. The more modest islet phenotype in the Rfx3-/mice may be due to the ability of Rfx2 to compensate partially for the loss of Rfx3 (Fig. 1a),
or the ability of Rfx6 to direct gene expression as a homodimer (Fig. 5a, b).

Human mutations in RFX6

Author Manuscript

The phenotype of the Rfx6 eGFPcre/eGFPcre mice is remarkably similar to human patients
born with neonatal diabetes and small bowel obstruction due to bowel atresia17, 18. Despite
some reduction in pancreatic size, these cases were not deficient in enzymes of the exocrine
pancreas, and autopsies of two cases (proband #1 and case 3 in Ref 17) revealed normalappearing exocrine pancreata with clusters of ChromograninA-positive cells but total
absence of cells staining for insulin, glucagon, or somatostatin17. In addition, the syndrome
involves hypoplastic gall bladder, and intractable diarrhea unresponsive to pancreatic
enzyme replacement.

Author Manuscript

The disease locus was mapped using overlapping homozygosity in probands #1and #2 (see
Supplementary material for pedigree information and references to previous clinical case
reports) respectively the offspring of first and second cousins. High-resolution
homozygosity mapping identified 10 homozygosity-by-descent (HBD) segments >500 kb in
proband #1 (after excluding those that overlapped with her unaffected sibling,
Supplementary Table S4), and 25 HBD segments >500kb in proband #2 (Supplementary
Table S5). Only three HBD regions were common in the two probands, totaling 24 Mb
(Table 1). Altogether, 194 RefSeq genes map to these regions. Of these genes, only RFX6,
which falls in the largest segment at 6q21-22, had pancreas–enriched expression in the
TiGER database 19 (Supplementary Table 6), and also increased in expression in human
pancreas between foetal ages 10 and 20 weeks (Fig. 1b and Supplementary Figs. S13 and
S14), concordant with the appearance of endocrine cells 20,21.
Two parallel, independent approaches unequivocally identified mutations in the RFX6 gene
in this human syndrome: direct sequencing of the RFX6 gene and unbiased deep sequencing
of all exons within the three overlapping HBD regions.

Author Manuscript

For deep sequencing, exons were captured from DNA obtained from Proband #2 using a
tiled oligonucleotide array22 covering 1,309 of 1,322 exons mapping within the HBD
regions23. Amplification and sequencing24 of the captured fragments generated 40,379
sequences of at least 100 bp that aligned within the target regions. Median target coverage
depth was 9.2, with 80% of targets having a depth of at least 4. Given that we were
searching for a homozygous mutation, this was sufficient for unequivocal detection of
exonic variants. Altogether, 30 novel sequence variants were detected (Supplementary Table
S7): 15 in introns, 3 in both introns and untranslated regions (UTRs), 9 in UTRs, and only
three in coding sequences, two synonymous. The only non-synonymous variant was 217
Ser>Pro in RFX6, identifying this gene as the most likely candidate.
In parallel, direct sequencing was performed on the 19 exons and the splicing junctions of
RFX6 in all probands. Missense, splicing or frameshift mutations in RFX6 were found in
five of the six available probands (Fig. 5e) with an interesting genotype-phenotype
Nature. Author manuscript; available in PMC 2010 August 11.
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correlation. Probands #1, 4 and 5 all died in the first few months of life and were
homozygous for, respectively, a loss of the donor splicing site in intron 2 (IVS2+2 t>c), an
out-of-frame deletion in exon 7, and the missense mutation 181 R>Q involving a highly
conserved arginine in the DNA-binding domain 8,25(Supplementary Fig. S15). Proband #3,
still alive at the age of 9 and intermittently off insulin, was a compound heterozygote for
donor-site loss in intron 6 (IVS6+2 t>g) and disruption of the acceptor site in intron 1
(IVS1-12 a>g). Proband #2, still alive at age 4.5 years18, had the homozygous missense
mutation 217 Ser>Pro, confirming the unbiased exon sequencing described above. All
mutations were inherited from carrier parents.

Author Manuscript

To determine the significance of the homozygous intron 2 splice donor splicing site
mutation in proband #1, we amplified RFX6 mRNA by RT-PCR of high-quality RNA from
autopsy pancreas and failed to detect the properly spliced transcript, which was easily
amplified from normal foetal pancreas as was the reference gene cyclophilin in the
proband’s RNA. We also failed to detect any RNA from exons 1+2, upstream of the splicing
mutation, probably due to nonsense-mediated decay26(Supplementary Fig. S16).
We also tested the two missense mutations for their effect on DNA binding by Rfx6. We
found that 181R>Q (proband #5), which alters a conserved amino acid in the DNA binding
domain, completely abrogated DNA binding, while 217S>P (proband #2), which lies
between the DNA-binding domain and dimerization domain of Rfx6, only modestly reduced
DNA binding (Fig. 5d) and did not affect dimer formation (data not shown).

Author Manuscript

Finally, we failed to identify any mutation in RFX6 in proband #6. In the absence of DNA
from the proband, we sequenced both parents and found no point mutation of RFX6 or
NEUROG3; and long-range PCR did not reveal any deletions of RFX6 (Supplementary Fig.
S17). In the absence of proband DNA we cannot rule out a de novo mutation, but this case is
most likely a phenocopy. We also failed to find RFX6 mutations in a case of the MartinezFrias syndrome27. Finally, a search of the RFX6 linkage disequilibrium block in our
genome-wide association data 28,29, combined with those of the WTCC 30, did not reveal
any common variants associated with type 1 or type 2 diabetes (data not shown).

Discussion

Author Manuscript

In the pancreas, Rfx6 acts downstream of the pro-endocrine factor Neurogenin3 (Fig. 5c),
and mutation of the two genes give similar but distinct phenotypes. Like RFX6 mutations,
mutation of NEUROG3 in humans also causes intractable diarrhoea and diabetes 31, but
NEUROG3 mutation does not cause the small bowel atresia or biliary abnormalities seen
with RFX6 mutation, which is not surprising since Neurogenin3 is not expressed in the early
gut endoderm as is Rfx6 4,32,33. Despite severe intestinal malabsorption, pancreatic exocrine
function is intact in both syndromes, and the only histological abnormality in the gut in the
mutant NEUROG3 syndrome is loss of the intestinal endocrine cells 34. Comparison of the
gut endocrine cells affected by these two related syndromes may provide new insight into
mechanisms that regulate nutrient absorption in the small bowel.
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In addition, RFX6 mutations cause diabetes at birth, while the reported patients with
homozygous mutations in Neurogenin3 did not develop diabetes until several years later 31,
despite evidence that Neurogenin3 is absolutely required for the generation of islet cells and
production of insulin in mice 2. Incomplete loss of function in the reported human
NEUROG3 mutations could explain the continued insulin production in these patients 35.
Alternatively, recent evidence that Neurog3-/- mice still generate a small number of islet
cells 36 suggests some redundancy of Neurogenin3’s pro-endocrine function, possibly due to
the presence of related bHLH proteins in the pancreas 4,7. In contrast, our data do not
indicate any redundancy of Rfx6 function in endocrine differentiation and demonstrate
remarkable conservation of the genetic control of islet development, despite some
discrepancy between mouse and human NEUROG3 mutants.

Author Manuscript

It should be noted that our patients with RFX6 mutations have some similarities with other
reported cases, especially those with the Martinez-Frias syndrome (MFS)27, under which
OMIM currently lists our cases. However, since the original MFS patients also had
oesophageal atresia and hypospadias, and did not have diabetes, and we did not find any
RFX6 mutation in the parents of one case of MFS, our cases are distinct from MFS. We
propose to name their condition, now of defined molecular aetiology, the Mitchell-Riley
syndrome after the two clinicians who first described it17.

Author Manuscript

In summary, we have identified a novel factor in endoderm and islet development, Rfx6,
that is required for the differentiation of 4 of the 5 islet cell types and for the production of
insulin in both humans and mice. In the hierarchy of islet developmental factors, it lies
downstream of Neurogenin3 and upstream of many of the other islet transcription factors
(Fig. 4d). A full understanding of the role of Rfx6 will help to clarify how islets and β-cells
are generated, what goes wrong in this process in diabetes, and how to generate new β-cells
for patients with diabetes.

Methods summary

Author Manuscript

All studies involving mice were approved by the UCSF Institutional Animal Care and Use
Committee. Timed matings were carried out with embryonic day 0.5 being set as midday of
the day of discovery of a vaginal plug. The Rfx6 targeting allele (Supplementary Fig. S8)
was generated by recombineering in a modified bacterial artificial chromosome followed by
recombination into plasmid DNA by gap-repair 38. This construct was used by the UCSF
DERC Transgenic Core Laboratory to target the Rfx6 allele in 129 (E14) mouse embryonic
stem cells, which were injected into mouse blastocysts to generate chimeric Rfx6 +/eGFPcre
mice. Chimeras and subsequent generations were crossed to C57BL/6 mice. Mouse tissue
processing, β-galactosidase detection, immunofluorescence staining 39, automated cell
counting 40, transfections of mPAC cells, EMSA 41 and mRNA quantification with low
density TaqMan arrays 6 were performed as previously described. All antisera used for
immunofluorescence studies are listed in Supplementary Table S8. Sequences of
oligonucleotides used for RT-PCR, ESC colony screening, mouse genotyping and EMSA
are available on request.
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The human subjects protocol was approved by the IRB of the Montreal Children’s Hospital
and written informed consent was obtained from all participating families. Clinical findings
and case-report references are summarized in the web supplement. For homozygosity
mapping, results from the Illumina Hap 550 (proband #1, call rate 0.99) or 1M (proband #2,
call rate 0.978) microarrays37, were used to scan autosomes in 300-kb windows and HBD
was defined as absence of any heterozygous SNP in the proband and presence of at least one
in either parent or the unaffected sibling. Long-oligo Nimblegen capture arrays22 included
around 100 bp extension of intronic sequence coverage from the boundary of the exons. The
eluted enriched regions from proband #1 were run on the Roche 454 FLX Genome
Sequencer24. The 19 exons of RFX6 were PCR-amplified manually for Sanger sequencing
in the remaining probands. For the long range PCR, we used the Kit # K0182 from
Fermentas for fragments ranging from 6 to 17 Kb (Supplementary Fig S17).

Author Manuscript
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Figure 1. Expression of Rfx6 in mice and human tissues
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In a, the mRNA for Rfx genes 1-6 were amplified by RT-PCR from RNA isolated from the
pancreas and brain of mouse embryos at e17.5 and from NIH3T3 fibroblasts. In b, levels of
RFX6 mRNA were determined by real-time PCR of RNA from whole pancreas of human
foetuses at the ages shown. n= 5 samples per foetal age group. *p= 0.017, weeks 8-10 vs.
19-21, by two-tailed Student’s t test. In c, mRNA for RFX6 and control gene Cyclophilin A
(PPIA) genes were amplified by RT-PCR from RNA isolated from the human adult tissues
shown. In d, levels of Rfx3 and Rfx6 mRNA were determined by real-time RT-PCR
(TaqMan) of RNA isolated from the pancreata of wildtype and Neurog3-/- mouse embryos at
e17.5 values and expressed relative to the level of Gusb. n= 3 samples per group. **p =
0.0025, wildtype vs. mutant, by two-tailed Student’s t test.
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Figure 2. Expression of Rfx6 in mice
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Immunofluorescence staining was performed for Rfx6 (red) in mouse embryos. In a - c, at
e9, Rfx6 staining overlaps with Foxa2 in the gut epithelium (including foregut, FG) and
nascent dorsal pancreatic bud (DP), but Foxa2 is expressed alone in the liver bud (Li) and
extraembryonic endoderm (EE). Separate colour channels are shown for red (a and d) and
green (b and e). In d - f, costaining was performed with Pdx1 (green) in gut (duodenum,
Du), dorsal pancreas (DP) and ventral pancreas (VP) at e10. In g, e15.5 pancreas was
costained for Neurogenin3 (green). Costaining nuclei appear yellow. In h, e18.5 pancreas
was costained for insulin (green). In i, adult pancreas was costained for insulin (green).
Higher resolution photomicrographs from additional dates with additional markers can be
found in Supplementary Figs. 1-7. Scale bars, 25 μm.
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Figure 3. Targeting of the Rfx6 gene in mice
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In panel a-d, lineage tracing was performed on Rfx6 +/+/R26R (left in a and c) or
Rfx6 +/eGFPcre/R26R (b and d, and right in a and c) mice at e10.5 (a, b) and e12.5 (c, d) by
staining for β-galactosidase activity with Xgal (blue). Panel b shows a close-up view of the
animal on the right in panel a, and panel d shows a close-up view of the animal on the right
in panel c. In panel e, an Rfx6eGFPcre/eGFPcre pup at p2 is shown on the right, with a
wildtype liter mate on the left. In panel f, the dissected abdominal viscera are shown for
wildtype (left) and Rfx6eGFPcre/eGFPcre (right) pups at p0.5. Additional photographs of the
lineage tracing and mutant animals can be found in Supplementary Fig. 10. Li, liver; Du,
duodenum; GB, gall bladder; VD, vitelline duct; Th, thymus; Tr, trachea; Oe, oesophagus;
Lu, lung; St, stomach; DP, dorsal pancreas; VP, ventral pancreas; Hg, hindgut.
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Figure 4. Expression patterns of islet markers in wildtype and Rfx6eGFPcre/eGFPcre mice at e17.5
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On pancreas sections from e17.5 embryos with the genotypes shown at the left,
immunofluorescence costaining was performed for ChromograninA (ChromoA, red, a - f,
green k, l), Synaptophysin (Syn, red, g, h), insulin (green, a, b), glucagon (green, c, d),
somatostatin (Sst, green, e, f), ghrelin (green g, h), Nkx6.1 (red in i - l), and pancreatic
polypeptide (Ppy, green, k, l). Quantification of cells expressing Ppy and Nkx6.1 is shown in
Supplementary Table S3. Scale bars, 25 μm.
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Figure 5. Function of the human Rfx6 protein
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In a and c, DNA binding of the human in vitro-translated proteins shown above each lane to
the double-stranded, radiolabeled oligonucleotide HBV X-box probe 42 was tested by
electromobility shift assay (EMSA). In a, combined proteins were co-translated, and probe
bound by the heterodimer partners has a mobility between that of the two homodimers.
Truncated proteins Rfx3T1 and Rfx3T2 have the first 119 and 160 amino-terminal amino
acids removed respectively, but retain the DNA-binding and dimerization domains. In vitrotranslated luciferase is included as a negative control. A close-up view of a longer gel is
shown in Supplementary Fig. S10a. In b, mouse pancreatic ductal mPac L20 cells were cotransfected with a DNA plasmid containing the reporter constructs shown and another
expressing the RFX cDNAs shown, luciferase reporter expression was assayed for each
combination. *p = 0.0026 vs. “no cDNA”, 0.0024 vs. Rfx3 alone, and 0.011 vs. Rfx6 alone
by two-tailed Student’s t test. In c, a schematic shows the proposed interactions, either direct
or indirect, of several transcription factors during pancreas development. In d, increasing
amounts of the in vitro-translated human Rfx6 wild type and R181Q and S217P mutant
proteins were assayed for binding to the X-box DNA probe. Efficiency of mutant protein
production is demonstrated in Supplementary Fig. S10b. In e, mutations found in patients
are indicated on a map of the RFX6 gene. All mutations were homozygous except for
proband 3.
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